Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12 Glioblastoma 2 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neoplasm Metastasis 1 Medulloblastoma 1 Inflammatory Breast Neoplasms 1 Her2 Positive Metastatic Breast Cancer 1 Head and Neck Neoplasms 1 HER2 Positive Metastatic Breast Cancer 1 Gliosarcoma 1 Familial ependymoma 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms, Male 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Docetaxel 33 Prednisone 28 enzalutamide 19 Abiraterone Acetate 13 pembrolizumab 11 gallium 68 PSMA-11 9 Leuprolide 9 Radiotherapy 8 Pluvicto 8 Magnetic Resonance Spectroscopy 8 Nivolumab 7 Estramustine 7 abiraterone 6 Radiotherapy, Intensity-Modulated 6 Goserelin 6 Carboplatin 6 Biopsy 6 olaparib 5 cemiplimab 5 bicalutamide 5 Specimen Handling 5 Paclitaxel 5 Cyclophosphamide 5 temsirolimus 4 orteronel 4 darolutamide 4 cabazitaxel 4 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4 Sirolimus 4 Radiosurgery 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Prostatic Neoplasms × Lapatinib × Clear all

NCT00953576 2018-09-04

KHLAD

Dana-Farber Cancer Institute

Phase 1/2 Terminated

11 enrolled 9 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡